Senti Biosciences is trading at $0.16, down 23.27%, as broader risk-off sentiment may have contributed; no fresh company-specific catalyst was identified.
- U.S. markets were under pressure, with the Nasdaq notably weaker. Technology shares also sold off amid concerns about earnings and outlooks; a direct link to Senti Biosciences’ move is unconfirmed.
- An October 28 filing noted a board resignation and an October 30 record date for previously announced CVRs, not a new October 30 catalyst.